50 results
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
cause us, an IRB or ethics committee, and/or regulatory authorities to interrupt, delay or halt clinical trials and could result in clinical trial … at the pleasure of the Compensation Committee rather than management, and the consultant’s fees are approved by the Compensation Committee.
Code of Ethics
We
424B5
MBRX
Moleculin Biotech Inc
22 Dec 23
Prospectus supplement for primary offering
5:00pm
regulatory bodies and ethics committees. The subject was treated for the infection, the SAE is still reported as “ongoing,” and the subject
8-K
EX-3.1
tjqmfx ce2
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
xl0a5ih2xp02iyye
11 Dec 23
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting
8:50am
8-K
EX-3.1
8cpqs
21 Aug 23
Amendments to Articles of Incorporation or Bylaws
5:17pm
8-K
twemwb9zslv36
21 Dec 22
Regulation FD Disclosure
8:25am
8-K
EX-99.1
a60n3d
15 Aug 22
Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
8:48am
8-K
EX-99.1
v36vnr0edc 58d8dp31
12 May 22
Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
8:35am
8-K
h0l9 9gwx
5 May 22
Regulation FD Disclosure
8:15am
8-K
EX-99.1
02b562j jgn
5 May 22
Regulation FD Disclosure
8:15am